AG10, a Novel, Potent and Selective Transthyretin Stabilizer, Is Well Tolerated at Doses Resulting in Target Therapeutic Blood Levels, and Demonstrates Clinical Proof-Of-Concept in Healthy Volunteers
Journal of Cardiac Failure - United States
doi 10.1016/j.cardfail.2018.07.091
Full Text
Open PDFAbstract
Available in full text
Date
August 1, 2018
Authors
Publisher
Elsevier BV